

IMPAACT Protocols Snapshot: In Development through Closed to Follow Up

Protocol #	Title	Sites	Study Status	Research Area	Protocol to Sites (Projected)	Open to Accrual (Projected)	1st Participant Enrolled (Projected)	Closed to Accrual (Projected)	Closed to Follow Up (Projected)	Target Accrual	Actual Accrual as of report date
IMPAACT 2047	Pharmacokinetics, Safety and Tolerability of High Dose Rifapentine Given With Moxifloxacin for Tuberculosis During Pregnancy (Radiant-Moms Plus)	TBD	In Development	Tuberculosis	31-Oct-25	TBD	TBD	TBD	TBD	TBD	NA
IMPAACT 2046	Understanding Parental Lactation and Infant Feeding Decisions Tailored to People with HIV (UPLIFT)	TBD	In Development	Brain & Mental Health	31-Oct-25	TBD	TBD	TBD	TBD	TBD	NA
IMPAACT 2044	Phase IV Study of the Pharmacokinetics and Safety of Ceftriaxone and Benzathine Penicillin G During Pregnancy	US	In Development	Therapeutics	31-Aug-25	30-Nov-25	31-Jan-26	31-Jul-26	30-Apr-27	58	NA
IMPAACT 2043/A5425	Postpartum Long-Acting Cabotegravir/rilpivirine (PRACTICAL) A Randomized Study of Long-Acting ART in Postpartum Women at Risk for Adherence Challenges	US/INTL	In Development	Therapeutics	TBD (see ACTG)	TBD	TBD	TBD	TBD	544 pairs	NA
IMPAACT 2020	Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children	INTL	In Development	Tuberculosis	31-Jul-25	28-Dec-25	28-Feb-26	28-Feb-28	28-Feb-29	112 children and their caregivers	NA
IMPAACT 2039	Phase I/II Randomized Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV (EXCEED)	US/INTL	In Development	Cure & Immunotherapy	30-Jun-25	28-Sep-25	27-Dec-25	TBD	TBD	42 (Part A); 40 (Part B)	NA
IMPAACT 2041	Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with or without HIV	US	In Development	Therapeutics	28-Feb-25	29-May-25	28-Jun-25	28-Jun-26	23-Feb-27	30 pairs	NA
IMPAACT 2024	Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to less than 13 Years of Age with and without HIV	INTL	In Development	Tuberculosis	14-Feb-25	14-May-25	14-Aug-25	14-Aug-27	13-Feb-28	90	NA
IMPAACT 2037	Open Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1	US/INTL	Pending	Therapeutics	09-Dec-24	31-Mar-25	30-Jun-25	30-Jun-26	30-Jun-28	48	NA
IMPAACT 2040	Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 (CREATE)	US/INTL	Pending	Therapeutics	16-Feb-24	01-Apr-25	01-May-25	30-Jan-27	30-Jan-28	45 pairs	NA
IMPAACT 2042	Phase I/II Trial to Evaluate the Impact of Three Broadly Neutralizing Antibodies or Analytic Treatment Interruption on Viral Reservoir, Immune Function, and Maintenance of HIV Suppression in Early-Treated Children in Botswana (Tatelo Plus)	INTL	Enrolling	Cure & Immunotherapy	09-May-24	23-Oct-24	11-Nov-24	08-Apr-25	27-Jul-27	approx 41	12
IMPAACT 2036	Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV Two to Less than 12 Years of Age (CRAYON)	US/INTL	Enrolling	Therapeutics	04-Oct-22	12-Dec-23	24-Jan-24	27-Jul-25	27-Jul-27	90	51

TBD = information is to be added once timeline is clearer
 Grey text boxes indicate a projected (rather than actual) date

Based on data available through 28 January 2025
 Page 1 of 2

IMPAACT Protocols Snapshot: In Development through Closed to Follow Up

Protocol #	Title	Sites	Study Status	Research Area	Protocol to Sites (Projected)	Open to Accrual (Projected)	1st Participant Enrolled (Projected)	Closed to Accrual (Projected)	Closed to Follow Up (Projected)	Target Accrual	Actual Accrual as of report date
IMPAACT 2034	Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis	INTL	Enrolling	Tuberculosis	04-Aug-22	17-Feb-23	03-Oct-23	01-Jan-26	15-Jan-26	72	25
IMPAACT 2023	A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1	US/INTL	Enrolling	Therapeutics	25-Oct-21	26-Sep-22	05-Oct-22	21-Jan-25 (pending confirmation of evaluability)	30-Jun-25	108	48
IMPAACT 2028	Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV Infection	US/INTL	Enrolling	Cure & Immunotherapy	31-Dec-20	08-Nov-21	02-Feb-22	30-Nov-26	30-Nov-27	250	159
IMPAACT 2026	Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum	US/INTL	Enrolling	Therapeutics	04-Feb-20	08-Jun-21	01-Sep-21	30-Apr-26	01-Sep-26	325	102 pairs
IMPAACT 2003b/A5300b	Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients ("PHOENIX MDR-TB")	INTL	Enrolling	Tuberculosis	2-Oct-18 (V2)	03-Jun-19	13-Jun-19	01-Feb-25	01-Feb-27	3557 (household); 1830 (index)	3905 (household); 1927 (index)
P1115	Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study	US/INTL	Enrolling	Cure & Immunotherapy	20-Mar-14	24-Jun-14	23-Jan-15	31-Dec-26	31-Dec-35	905 pairs	892 pairs
IMPAACT 2005	A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children with MDR-TB with and without HIV	INTL	Closed to Accrual	Tuberculosis	21-Mar-17	30-Jan-18	18-Feb-19	08-Nov-24	11-Sep-26	48	37
IMPAACT 2016	Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings	INTL	Closed to Accrual	Brain & Mental Health	08-Nov-18	27-Nov-19	11-Nov-23	03-Oct-24	03-Oct-25	256 pairs (randomized trial)	254 youth, 230 caregivers (randomized trial)
P1108	A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children, and Adolescents with RR-TB Disease, Living with or without HIV	INTL	Closed to Accrual	Tuberculosis	09-Mar-16	18-Aug-17	21-Sep-17	25-Aug-23	08-Aug-25	54	54
IMPAACT 2017	Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents (MOCHA)	US/INTL	Closed to Accrual	Therapeutics	16-Mar-18	19-Mar-19	03-Apr-19	03-Aug-23	31-Mar-25	155	155
Research Area: Brain & Mental Health				2046, 2016							
Cure & Immunotherapy				2042, 2039, 2028, P1115							
Therapeutics				2044, 2043/A5425, 2041, 2040, 2037, 2036, 2026, 2023, 2017							
Tuberculosis				2047, 2034, 2024, 2020, 2005, 2003b/A5300b, P1108							

TBD = information is to be added once timeline is clearer
 Grey text boxes indicate a projected (rather than actual) date

Based on data available through 28 January 2025
 Page 2 of 2